On Friday, Y-Mabs Therapeutics Inc (NASDAQ: YMAB) opened lower -3.38% from the last session, before settling in for the closing price of $8.57. Price fluctuations for YMAB have ranged from $6.09 to $20.90 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 37.03%. Company’s average yearly earnings per share was noted -28.29% at the time writing. With a float of $37.22 million, this company’s outstanding shares have now reached $44.77 million.
Let’s determine the extent of company efficiency that accounts for 100 employees. In terms of profitability, gross margin is 88.83%, operating margin of -33.66%, and the pretax margin is -27.28%.
Y-Mabs Therapeutics Inc (YMAB) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Y-Mabs Therapeutics Inc is 16.91%, while institutional ownership is 60.19%. The most recent insider transaction that took place on Sep 13 ’24, was worth 875,550. In this transaction CHIEF BUSINESS OFFICER of this company sold 65,000 shares at a rate of $13.47, taking the stock ownership to the 97,681 shares. Before that another transaction happened on Sep 16 ’24, when Company’s CHIEF BUSINESS OFFICER sold 30,000 for $12.97, making the entire transaction worth $389,100. This insider now owns 67,681 shares in total.
Y-Mabs Therapeutics Inc (YMAB) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -28.29% per share during the next fiscal year.
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Trading Performance Indicators
Check out the current performance indicators for Y-Mabs Therapeutics Inc (YMAB). In the past quarter, the stock posted a quick ratio of 3.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.54, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.60 in one year’s time.
Technical Analysis of Y-Mabs Therapeutics Inc (YMAB)
Looking closely at Y-Mabs Therapeutics Inc (NASDAQ: YMAB), its last 5-days average volume was 0.49 million, which is a jump from its year-to-date volume of 0.33 million. As of the previous 9 days, the stock’s Stochastic %D was 5.59%. Additionally, its Average True Range was 0.80.
During the past 100 days, Y-Mabs Therapeutics Inc’s (YMAB) raw stochastic average was set at 3.50%, which indicates a significant decrease from 7.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.63% in the past 14 days, which was lower than the 68.97% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.41, while its 200-day Moving Average is $13.15. However, in the short run, Y-Mabs Therapeutics Inc’s stock first resistance to watch stands at $8.52. Second resistance stands at $8.76. The third major resistance level sits at $9.03. If the price goes on to break the first support level at $8.02, it is likely to go to the next support level at $7.75. Should the price break the second support level, the third support level stands at $7.51.
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Key Stats
There are currently 44,789K shares outstanding in the company with a market cap of 358.30 million. Presently, the company’s annual sales total 84,820 K according to its annual income of -21,430 K. Last quarter, the company’s sales amounted to 18,460 K and its income totaled -7,000 K.
